文献速递前列腺癌

澳大利亚前列腺mpMRI资助减少穿刺活检并节省医疗支出

Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer.
PubMed 文献 · BJU Int · 2020-10-06

该研究基于澳大利亚Medicare 2007–2019年统计,分析mpMRIp引入对前列腺穿刺活检数量的影响,并按MSAC模型估算费用节省。结果显示,自2012年mpMRIp可用后,校正PSA检测变化,活检平均每月减少354.7例(95%CI 175–534.4;

要点

  • mpMRIp可用后前列腺活检平均每月减少354.7例(95%CI 175–534.4;P<0.001)
  • 政府资助mpMRIp可能改善健康公平并节省医疗支出

研究设计与样本

  • 基于澳大利亚Medicare公开数据库2007年7月1日至2019年6月30日PSA检测、前列腺活检和mpMRIp统计数据的分析。
  • 分析分为2007–2012(无mpMRIp)、2012–2018(mpMRIp可用但私人资助)、2018–2019(mpMRIp可用且有Medicare资助)三个时段。
  • 以PSA检测数量作为控制变量,并分析MSAC提出的经济学模型以评估费用节省。

主要发现

  • 校正PSA检测变化后,自2012年引入mpMRIp起,前列腺活检数量平均每月减少354.7例(95%CI 175–534.4;P<0.001)。

临床怎么用

  • 在澳大利亚背景下,政府资助mpMRIp可作为减少不必要前列腺活检并节省医疗支出的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of the introduction of multiparametric magnetic resonance imaging of the prostate (mpMRIp) on the number of prostate biopsies performed in Australia. METHODS: Australian Medicare published statistics from 1 July 2007 to 30 June 2019 were obtained from publically available databases for prostate-specific antigen (PSA) testing, prostate biopsy, and mpMRIp. Analysis was divided into three time periods broadly based on availability of mpMRI to the Australian public: 2007-2012 (no mpMRIp), 2012-2018 (mpMRIp available, privately funded), and 2018-2019 (mpMRIp available with Medicare funding). Introduction of mpMRIp was hypothesised to reduce the number of prostate biopsies performed. PSA testing numbers were used as a control. The economics model, proposed by the Medical Services Advisory Committee (MSAC), was analysed for cost savings. RESULTS: Accounting for variations in PSA testing, the introduction of mpMRIp from 2012 coincided with a reduction in the number of prostate biopsies by an average of 354.7/month (95% CI 175, 534.4; P < 0.001). Whilst the number of mpMRIp performed for the initial 12 months was underestimated by the MSAC at 38 470 vs 20 149 (+$8.3 million Australian dollars), we estimate the annual savings from reduced number biopsies and biopsy-associated complications to be $13.2 ± 9.6 million. CONCLUSION: Availability of mpMRIp in Australia has correlated with a significant reduction in prostate biopsy rates, with an estimated annual saving of $13.2 ± 9.6 million. Government funding of this diagnostic service has the potential to improve health equity and save on health expenditure.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Whish-Wilson T, Costello D, Finch S, et al. Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer. BJU Int. 2020. PMID: 33025681. doi:10.1111/bju.15231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。